We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 61

Takeaways from Federal Circuit’s Decision in UCB v. Accord on Obviousness of Chemical Compounds
  • Paul Hastings LLP
  • USA
  • June 4 2018

In a recent split decision in UCB v. Accord, the Federal Circuit affirmed a finding that claims covering a pharmaceutical compound were not invalid


Berkheimer and Aatrix En Banc Denial: a Divided Federal Circuit on Alice Step Two
  • Paul Hastings LLP
  • USA
  • June 4 2018

This week, the Federal Circuit issued virtually identical orders denying petitions for panel rehearing and rehearing en banc filed by petitioners in


Federal Circuit Speaks on Patent Eligibility of Method-of-Treatment Claims: Key Takeaways from the Vanda v. West-Ward Decision
  • Paul Hastings LLP
  • USA
  • April 16 2018

On April 13, 2018, the Federal Circuit held that a Hatch-Waxman plaintiff’s patent claims concerning methods of treating schizophrenia were not


PTAB Section 315(b) Time-Bar Determinations Reviewable at the Federal Circuit
  • Paul Hastings LLP
  • USA
  • January 10 2018

In a 9-4 en banc opinion issued on Monday, the Federal Circuit held that the Patent Trial and Appeal Board’s (“PTAB” or “Board”) time-bar


Federal Circuit Provides Additional Guidance for Induced Infringement in Hatch-Waxman Cases
  • Paul Hastings LLP
  • USA
  • November 13 2017

On November 9, 2017, the Federal Circuit confirmed that the overall content of a generic drug manufacturer’s labeling, as well as real-world evidence


Federal Circuit Reverses Judge Sleet’s Factual Findings for Failure to Address Unrebutted Evidence
  • Paul Hastings LLP
  • USA
  • November 3 2017

On November 1, 2017, the Federal Circuit reversed Judge Sleet’s (District of Delaware) decision that Bayer’s asserted patent was not invalid for


Aqua Products, Inc. v. Matal: Petitioners Bear the Burden of Establishing the Unpatentability of Amended Claims in IPR Proceedings
  • Paul Hastings LLP
  • USA
  • October 10 2017

Upending the current motion-to-amend practice before the Patent Trial and Appeal Board (“the PTAB”), a deeply fractured en banc Federal Circuit in


No Physical Place, No Regular and Established Place of Business: The Federal Circuit Strikes Down Judge Gilstrap’s Patent Venue Framework
  • Paul Hastings LLP
  • USA
  • September 25 2017

Last Thursday, the Federal Circuit granted a petition for writ of mandamus from Cray Inc., striking down a venue test advanced by Judge Gilstrap in


Visual Memory LLC v. NVIDIA Corp.: Panel-dependency for 101 Challenges at the 12(b)(6) Stage
  • Paul Hastings LLP
  • USA
  • August 23 2017

In Visual Memory LLC v. NVIDIA Corp., No. 2016-2254 (Fed. Cir. Aug. 15, 2017), a divided panel at the Federal Circuit applied an analytical framework


No Article III Standing Requirement for Appellees in Appeals From IPR Proceedings
  • Paul Hastings LLP
  • USA
  • August 8 2017

In a precedential decision issued August 7, 2017, Personal Audio, LLC v. Electronic Frontier Foundation, No. 2016-1123 (Fed. Cir. Aug. 7, 2017), the